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Nitric oxide mediates glial-induced
neurodegeneration in Alexander disease
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Glia play critical roles in maintaining the structure and function of the nervous system;
however, the speciﬁc contribution that astroglia make to neurodegeneration in human disease
states remains largely undeﬁned. Here we use Alexander disease, a serious degenerative
neurological disorder caused by astrocyte dysfunction, to identify glial-derived NO as a
signalling molecule triggering astrocyte-mediated neuronal degeneration. We further ﬁnd that
NO acts through cGMP signalling in neurons to promote cell death. Glial cells themselves
also degenerate, via the DNA damage response and p53. Our ﬁndings thus deﬁne a speciﬁc
mechanism for glial-induced non-cell autonomous neuronal cell death, and identify a
potential therapeutic target for reducing cellular toxicity in Alexander disease, and possibly
other neurodegenerative disorders with glial dysfunction.
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A
strocytes are now known to inﬂuence a variety of complex
nervous processes including sleep, learning and
memory, and breathing1,2. At the molecular and cell
biological levels, astrocytes play a critical role in regulating the
permeability of the blood–brain barrier, responding to oxidative
stress, modulating synaptic transmission and controlling
synaptogenesis and synaptic pruning. Given the plausible role
many of these processes play in neuronal dysfunction and death
during neurodegeneration, astrocytes seem poised to be critical
players in neurodegenerative disorders. Indeed, morphological
changes in astrocytes are prominent in all neurological disorders
characterized neuropathologically by signiﬁcant cell loss or tissue
damage. However, rigorously deﬁning a role for astrocytes in
neurodegenerative disorders has been challenging. First, in most
disorders, neuronal pathology is quite prominent, raising the
possibility that changes in glial cells are secondary phenomena.
Second, it has been challenging to identify the molecular
underpinnings of glial-induced neuronal death and test
cell-type-speciﬁc mechanisms in vivo.
To address these limitations, we have developed a model of a
glial-based neurodegenerative disorder, Alexander disease, in the
genetically accessible model organism Drosophila. Alexander
disease offers a unique opportunity to study glial-mediated
neurodegeneration, because the primary abnormality in patients
is glial: dominant missense mutations in the gene encoding glial
ﬁbrillary acidic protein (GFAP), the intermediate ﬁlament of
astrocytes3. Clinical presentations of this rare, but informative,
disorder range from infants with prominent leukodystrophy and
seizures to adults with relative preservation of myelin and a
movement disorder4,5. In all cases, the speciﬁc neuropathological
manifestation of Alexander disease is the formation of
eosinophilic, beaded inclusions termed Rosenthal ﬁbres within
astrocytes. Given evidence from patients and mouse models3,6,7
for a toxic dominant gain-of-function mechanism related to
abnormal aggregation and toxicity of GFAP in Alexander disease,
we have modelled the disorder by expressing disease-linked forms
of human GFAP in ﬂy glia8. Our Drosophila model replicates key
features of the human disorder, including formation of Rosenthal
ﬁbre-like inclusions, seizures and non-cell autonomous
neurodegeneration. At the molecular level, protein misfolding,
oxidative stress and dysregulated glutamate transport are critical
mediators of disease pathogenesis in our ﬂy model, correlating
well with results from mice and analysis of human tissue7,9–11.
An important, perhaps the most important, strength of
studying human disease in Drosophila is the ability to
perform unbiased forward genetic screens, which have the
potential to provide hypothesis-independent insights into disease
pathogenesis. Accordingly, we have performed genetic screening
in our ﬂy model of Alexander disease. Through our screen, we
identify nitric oxide (NO) as a critical mediator of non-cell
autonomous neurodegeneration. Further, to dissect the cell-type
speciﬁcity of the effect, we develop a system to manipulate gene
expression independently in neurons and glia. Using a newly
developed dual-expression system, we demonstrate a key role for
NO synthesized and released in glia acting through neuronal NO
targets to promote neuronal cell death.
Results
NO signalling is upregulated in Drosophila Alexander disease.
Our Drosophila model of Alexander disease is based on
expression of human disease-associated mutant GFAPR79H in ﬂy
glia using the standard GAL4/UAS bipartite expression system12
and the glial-speciﬁc driver repo-GAL4 (refs 8,13). Our model
recapitulates multiple aspects of authentic Alexander disease,
including glial toxicity and secondary non-cell autonomous
neurodegeneration8. To identify genetic modiﬁers of GFAP
toxicity in an unbiased pattern, we performed an unbiased
forward genetic screen using a collection of 2,239 transgenic
RNA interference (RNAi) lines14. To monitor toxicity of GFAP
to glia under screening conditions, we used the transgenic caspase
reporter developed by Williams et al.15 By monitoring caspase
activation in 10-day-old adult ﬂies expressing GFAPR79H
and RNAi targeting individual genes in glial cells, we recovered a
number of candidate suppressors and enhancers of GFAP toxicity.
One of these candidate suppressors was nitric oxide synthase (Nos).
Because NO represents a novel, but plausible, glial-derived
neuronal cell death signalling molecule in Alexander disease, we
explored NO signalling further in our Alexander disease model.
We ﬁrst examined levels of Nos protein (encoded by a single Nos
gene in ﬂies16) in control and GFAPR79H transgenic animals using
a rabbit polyclonal antibody to Drosophila Nos17. A signiﬁcant
increase in Nos in GFAPR79H ﬂies compared with controls was
detected by western blot analysis (Fig. 1a). Double-label
immunoﬂuorescence using neuronal- and glial-speciﬁc markers
conﬁrmed the presence of Nos in glial cells (Supplementary
Fig. 1a). The speciﬁcity of the antiserum was conﬁrmed on both
western blot and immunostaining using the NosD15 allele, a
deletion mutant of Nos removing the entire oxygenase domain17
(Supplementary Figs 1a and 2b). To probe Nos activity in our
GFAPR79H transgenic ﬂies, we performed nicotinamide adenine
dinucleotide phosphate (NADPH)-diaphorase histochemistry18.
Consistent with Nos protein upregulation, signiﬁcantly increased
NADPH-diaphorase staining was present in GFAPR79H transgenic
ﬂies (Fig. 1b). In addition, with a sensitive and speciﬁc NO sensor,
Cu2(FL2E)19, we observed signiﬁcantly increased in vivo NO
production in the brains of GFAPR79H transgenic ﬂies compared
with controls (Fig. 1c). To explore potential mechanisms
responsible for upregulation of Nos in our transgenic animals,
we evaluated the activity of a well-characterized reporter of
STAT expression, 10XSTAT-GFP20. We observed upregulation of
STAT expression speciﬁcally in GFAPR79H transgenic ﬂies
(Supplementary Fig. 1b).
We then examined the effect of GFAPR79H expression on
cellular pathways downstream of NO production. NO reacts with
superoxide (O2 ) to make peroxynitrite (ONOO ), a reactive
oxidant and cytotoxic agent that can nitrate tyrosine residues
of proteins; these modiﬁed proteins represent an important
indicator of nitrosative stress21. Western blot analysis performed
with a previously characterized polyclonal anti-nitrotyrosine
antibody22–24 demonstrated increased levels of nitrotyrosine-
containing proteins in GFAPR79H transgenic ﬂies compared with
controls (Fig. 1d). Soluble guanylate cyclase (sGC) is an
important speciﬁc target of NO-mediated nitrosylation25.
Nitrosylation of sGC activates the enzyme and increases cyclic
guanosine monophosphate (cGMP) production. cGMP, in turn,
is an important second messenger for a number of downstream
targets, including cyclic nucleotide-gated channels (CNGs25).
Using a sensitive chemiluminescent immunoassay, we found
signiﬁcantly increased levels of cGMP in brains of GFAPR79H ﬂies
compared with controls (Fig. 1e).
We also investigated levels of Nos protein, nitrotyrosine-
containing proteins and cGMP in transgenic ﬂies that express
wild-type human GFAP (GFAPWT) at levels equivalent to
GFAPR79H, and show no evidence of toxicity or inclusion
formation (Supplementary Fig. 1f, GFAPWT)8. We detected no
signiﬁcant difference in Nos protein levels, nitrotyrosine-
containing proteins or cGMP levels between GFAPWT
transgenic ﬂies and control ﬂies (Supplementary Fig. 1c–e),
demonstrating speciﬁcity for disease-associated mutant
GFAPR79H. However, as seen in murine models, increased
expression of wild-type human GFAP does result in the
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formation of Rosenthal ﬁbre-like inclusions (Supplementary
Fig. 1f, 2 GFAPWT). We further investigated three additional
Alexander disease-associated mutant forms of GFAP,
GFAPR239H, GFAPL352P and GFAPA364P. Each of these mutant
forms of GFAP formed Rosenthal ﬁbre-like inclusions in
Drosophila glia (repo-GAL4 driver; Supplementary Fig. 1g,h).
We also observed inclusion formation when human mutant
GFAP was expressed in speciﬁc glial subtypes (Supplementary
Fig. 1i,j), including astrocyte-like glia (alrm-GAL4 driver) and
ensheathing glia (mz0709-GAL4 driver)26. However, we did not
observe signiﬁcant cellular toxicity with expression in either of
these glial subtypes, most likely due to lower levels of transgene
expression mediated by these drivers, as demonstrated by reduced
b-galactosidase (b-gal) expression mediated by alrm-GAL4
compared with repo-GAL4 (Supplementary Fig. 1k).
Modulation of Nos signalling alters GFAP toxicity in vivo. To
determine whether GFAP toxicity is inﬂuenced by Nos activity,
we ﬁrst manipulated the single Drosophila Nos gene genetically.
Overexpressing Nos in glia using a UAS-Nos transgene and
the glial driver repo-GAL4 markedly increased the number of
TdT-mediated dUTP nick end labelling (TUNEL)-positive cells,
while reducing Nos with either of the two independent transgenic
RNAi lines signiﬁcantly decreased the number of TUNEL-
positive cells in the brains of GFAPR79H ﬂies (Fig. 2a,e;
Supplementary Fig. 2a). Increasing Nos in the absence of
transgenic human GFAPR79H did not produce toxicity
(Fig. 2a). Western blot analysis demonstrated marked reduction
in Nos levels following RNAi-mediated gene knockdown
(Supplementary Fig. 2b). To ensure that modulation of
GFAP toxicity was not simply due to alterations in GFAP
protein levels, we examined GFAP expression in genetically
modiﬁed backgrounds and observed equivalent GFAP
protein levels (Supplementary Fig. 2c). Consistent with positive
TUNEL staining, the nuclei of dying cells were often condensed
(43.36±2.06%) and fragmented (32.82±1.64%) in GFAP
transgenic ﬂies (Supplementary Fig. 2d). Signiﬁcant numbers of
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Figure 1 | NO signalling is upregulated in GFAPR79H transgenic ﬂies. (a) Western blot shows increased expression of Nos in GFAPR79H transgenic ﬂies.
The blot was reprobed for actin to illustrate equivalent loading. Quantiﬁcation of Nos protein levels in control and GFAPR79H transgenic ﬂies is shown in the
graph at the right. *P¼0.0078, t¼ 6.371, df¼ 3; unpaired t-test, n¼4. (b) NADPH-diaphorase staining is increased in the brain of GFAPR79H transgenic
ﬂies. Quantiﬁcation is shown in the graph at the right. *P¼0.0021, t¼ 5.800, df¼ 5; unpaired t-test, n¼ 6 per genotype. (c) Time-lapse imaging reveals
increased nitric oxide production in vivo in GFAPR79H transgenic ﬂies with a nitric oxide sensor Cu2(FL2E). Scale bar, 10mm. *Po0.05, t¼ 2.833 (6min);
3.173 (8min); 3.137 (10min); two-way ANOVA, n¼ 7 per genotype. (d) Nitrotyrosine (N-tyr)-modiﬁed proteins are increased in GFAPR79H ﬂies.
*P¼0.0273, t¼ 2.902, df¼6; unpaired t-test, n¼4 per genotype. (e) Signiﬁcantly increased cGMP in GFAPR79H transgenic ﬂies as assayed by the
chemiluminescent immunoassay kit. **Po0.0001, t¼ 6.109, df¼ 16; unpaired t-test, n¼9 per genotype. Flies were 20 days old in all panels. Control (Ctrl)
is repo-GAL4/þ . GFAPR79H is repo-GAL4, UAS-GFAPR79H/þ .
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cells with cleaved caspase (Dcp-1) were present, and activation of
hid and th (also known as Diap1), key regulators of apoptosis, was
observed using transgenic reporter lines27,28 (Supplementary
Fig. 2e–g). To explore the speciﬁcity of our ﬁndings, we altered
activity of the Nos pathway in ﬂies expressing mutant human
ataxin 3, the aggregation-prone polyglutamine expanded protein
expressed in patients with spinocerebellar ataxia type 3, in glia29.
Nos pathway modiﬁers, including Nos overexpression and
knockdown, did not alter the toxicity of mutant ataxin 3 as
monitored by vacuolation in the brains of transgenic animals
(Supplementary Fig. 2h).
In addition to cell death, our Alexander disease model ﬂies also
exhibit seizure activity8. We therefore assessed the inﬂuence of
Nos on seizure frequency in GFAPR79H transgenic ﬂies. As with
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Figure 2 | Genetic and pharmacological modulation of Nos activity alters GFAPR79H toxicity. Nos was overexpressed with a UAS-Nos transgene (Nos
OE) and reduced with UAS-Nos RNAi lines (Nos RNAi). GFAP represents UAS-GFAPR79H. (a) The number of TUNEL-positive cells is increased in
GFAPR79H transgenic ﬂies with overexpression of Nos (Nos OE) and decreased with reduced expression of Nos (Nos RNAi). **Po0.0001, F¼ 72.53,
df¼ 29; n¼ 6 per genotype. Flies were 20 days old. Genotypes are indicated in the ﬁgure label. Driver: repo-GAL4. (b) Seizure frequency is increased with
overexpression of Nos (Nos OE) and decreased with reduced expression of Nos (Nos RNAi). *P¼0.0264, w2¼4.926, df¼ 1; **Po0.0001, w2¼ 24.731,
df¼ 1; n4100 per genotype. Flies were 1 day old. Genotypes are indicated in the ﬁgure label. Driver: repo-GAL4. (c) The Nos inhibitor L-NAME reduces the
number of TUNEL-positive cells in GFAPR79H transgenic ﬂies in a dose-dependent manner while D-NAME, the inactive enantiomer, shows no effect.
*Po0.01, **Po0.001, F¼ 12.41, df¼ 27; nZ6 per condition. Flies were 15 days old. Genotype: repo-GAL4, UAS-GFAPR79H/þ . (d) Seizure frequency is
reduced with L-NAME administration, but not with D-NAME. **Po0.0001, w2¼ 24.987, df¼ 1; w2¼ 24.083, df¼ 1; n4100 per condition. Flies were 3 days
old. Genotype: repo-GAL4, UAS-GFAPR79H/þ . (e) Overexpression of Nos (Nos OE) increases, while reduced Nos expression (Nos RNAi) decreases the
total number of TUNEL-positive cells (total, left), including both dying neurons (middle) and glia (right) in GFAPR79H transgenic ﬂies. **Po0.0001,
F¼ 13.18; 9.627; 17.06; df¼ 23; 23; 23; n¼ 6 per genotype. Flies were 20 days old. Genotypes are indicated in the ﬁgure label. Driver: repo-GAL4. þ :
repo-GAL4, UAS-GFAPR79H/þ . Statistical tests: one-way ANOVA with Tukey’s multiple comparison test in a,c and e; w2-test in b and d.
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cell death, increased Nos exacerbated seizure activity, while Nos
knockdown decreased seizure frequency (Fig. 2b). Thus,
manipulation of Nos levels inﬂuences disease-relevant
behaviour in our model.
Nos activity can also be controlled pharmacologically. L-NAME
is a well-characterized Nos inhibitor with documented activity in
Drosophila; D-NAME is the inactive enantiomer of L-NAME30.
To extend our genetic results and assess Nos as a potential
therapeutic target, we fed ﬂies orally with either L-NAME or
D-NAME. We found that inhibition of Nos activity with L-NAME
decreased cell death and seizure frequency, while D-NAME did
not alter cell death or the number of seizures in GFAPR79H
transgenic ﬂies (Fig. 2c,d; Supplementary Fig. 2i). L-NAME had
no effect on the levels of GFAP protein (Supplementary Fig. 2j).
In our ﬂy model of Alexander disease, expression of GFAPR79H
speciﬁcally in glia triggers non-cell autonomous neurodegenera-
tion8, as also occurs in human patients5,31. Since NO is a
diffusible signalling molecule, we hypothesized that NO released
from glia triggers neuronal cell death. To begin to test our
hypothesis, we examined glial and neuronal cell death in
GFAPR79H ﬂies with altered levels of Nos. We and others have
previously observed loss of endogenous cell-type-speciﬁc markers
in apoptotic cells8,32. We therefore introduced b-gal, expressed
using UAS-lacZ and repo-GAL4, as a transgenic marker and
performed double labelling with TUNEL to identify dying glia
speciﬁcally and distinguish neuronal from glial cell death
(Supplementary Fig. 2k). With our cell-type-speciﬁc labelling
of apoptotic cells, we observed that overexpression of Nos in
glia signiﬁcantly promoted neuronal cell death, consistent with a
non-cell autonomous effect of glial NO release (Fig. 2e, middle).
However, we also observed modestly increased glial cell death
with Nos overexpression, as well as reduction in both neuronal
and glial cell death with Nos knockdown. These data are
consistent with effects of Nos on toxicity in both cell types. Thus,
to test the speciﬁc role of NO in neurons we wanted to block the
effects of glial-derived NO in neurons. Given our evidence for
increased cGMP in GFAPR79H transgenic ﬂies (Fig. 1e), we
decided to focus on the NO target sGC. In Drosophila, genes
encoding the alpha and beta subunits of sGC, Gyca99B and
Gycb100B, have been identiﬁed and functionally characterized33.
To independently and simultaneously manipulate gene
expression in neurons and glia, we constructed a dual-glial–
neuronal expression system by combining the GAL4/UAS system
and the Q system12,34. The Q system is a bipartite expression
system, which is conceptually similar to the GAL4/UAS system
but instead relies on the regulatory genes from the Neurospora qa
gene cluster. The GAL4/UAS and Q systems do not interact and
can thus be used for independent simultaneous manipulation of
gene expression34.
Our strategy for independent manipulation of glial and
neuronal gene expression is illustrated in Fig. 3a. GFAPR79H
(QUAS-GFAPR79H) was expressed in glia using the Q system glial
driver ET31-QF34. These transgenic ﬂies have frequent Rosenthal
ﬁbre-like inclusions and increased seizure frequency
(Supplementary Fig. 3a–c), recapitulating the phenotypes
observed when GFAPR79H is expressed in glia with repo-GAL4
driver8. Transgenic RNAi targeted to Gyca99B and Gycb100B was
then expressed in neurons using the elav-GAL4 driver.
b-Galactosidase was expressed in neurons via UAS-lacZ and
elav-GAL4 as a control for expression of an unrelated protein in
neurons. Using the dual-expression system, we found that GFAP
toxicity was markedly reduced when sGC expression was reduced
speciﬁcally in neurons using either of the two independent RNAi
lines targeting Gyca99B or Gycb100B (Fig. 3b; Supplementary
Fig. 3g, left). Reduction in GFAP toxicity was not due to
alterations in GFAP protein levels, as determined by western blot
analysis (Supplementary Fig. 3d). We veriﬁed signiﬁcant
reductions in messenger RNA for Gyca99B and Gycb100B
with expression of transgenic RNAi targeting these loci using
RT–PCR (Supplementary Fig. 3e,f). Taken together, these data
support our hypothesis that glial-derived NO activates neuronal
sGC to mediate glia-induced non-cell autonomous neuronal
cell death. As with manipulation of Nos in glia, sGC knockdown
in neurons rescued both neuronal and glial cell death (Fig. 3b;
Supplementary Fig. 3g, middle and right). Identiﬁcation
of TUNEL-positive cells as neurons or glia in Fig. 3b was
based on morphology, as informed by cell-type-speciﬁc labelling
experiments (Fig. 2e), given difﬁculties encountered in
introducing an additional transgene into the complex genotypes
illustrated in Fig. 3a.
iNOS signalling is upregulated in Alexander disease mice. To
further investigate the role of NO signalling in Alexander disease,
we probed the pathway in two well-characterized mouse models
of the disorder. Mice expressing either a disease-associated point
mutant (GFAPþ /R236H) or wild-type human GFAP (GFAPTg)
develop clinical and pathological features reminiscent of human
Alexander disease, with GFAPTg mice exhibiting more pathology
compared with mice heterozygous for the knock-in allele6,7.
Compared with the single Nos locus in Drosophila, mammals
have three distinct NOS genes with encoded proteins having
different cellular localization, regulation, catalytic properties and
inhibitor proﬁles: neuronal NOS (nNOS or NOS1), inducible
NOS (iNOS or NOS2) and endothelial NOS (eNOS or NOS3)35.
We focused our investigations ﬁrst on nNOS and iNOS, because
in the brain eNOS is mainly expressed in vascular endothelial
cells, while nNOS and iNOS are mainly expressed in neurons and
astrocytes, respectively, and have been implicated in glial and
neuronal apoptosis35. Using an nNOS-speciﬁc antibody, we were
not able to detect differences in nNOS expression between
Alexander disease model mice and controls (Supplementary
Fig. 4a). In contrast, we observed signiﬁcant induction of iNOS in
Alexander disease model mice. Western blot analysis revealed
increased iNOS expression in the cortex of GFAPTg mice
compared with age-matched littermate controls (Fig. 4a).
Similarly, double-label immunoﬂuorescence revealed increased
iNOS in astrocytes (Fig. 4c; Supplementary Fig. 8), which was
validated by a second antibody reagent (Supplementary Fig. 4b).
We also examined downstream components of the pathway
and observed a prominent increase in nitrotyrosine-containing
proteins by both western blot analysis (Fig. 4b) and
immunostaining with a polyclonal anti-nitrotyrosine anti-
body22–24 (Fig. 4c; Supplementary Fig. 8). To conﬁrm and
extend prior characterization22–24, the anti-nitrotyrosine
antibody was validated using nitrated BSA on immunoblot and
tissue sections or by reducing nitrotyrosine to aminotyrosine on
tissue sections with dithiothreitol in a dose-dependent manner36
(Supplementary Fig. 4c). In addition, a second monoclonal
anti-nitrotyrosine antibody37,38 was used for additional
conﬁrmation (Supplementary Fig. 4d,e). Similarly, we observed
upregulation of cGMP and the CNG channel alpha 4 (CNGA4) in
astrocytes (Fig. 4c; Supplementary Fig. 9). Upregulation of each
marker was seen in both GFAPþ /R236H and GFAPTg, with
greater increases in GFAPTg mice compared with GFAPþ /R236H
animals, consistent with more severe neuropathological changes
in the animals overexpressing wild-type GFAP6,7. iNOS pathway
upregulation was seen in multiple regions of the nervous system,
including neocortex (Fig. 4c), corpus callosum and hippocampus
(Supplementary Fig. 4f). To evaluate the speciﬁcity of iNOS
induction, we also examined brain tissue from a widely used
transgenic mouse model of tauopathy based on expression of
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human P301L mutant tau. These mice show signiﬁcant
astrogliosis and formation of insoluble tau-containing protein
aggregates at 7 months of age39. We did not observe signiﬁcant
upregulation of iNOS in astrocytes of tauopathy model mice
(Supplementary Fig. 4g).
Oxidative stress and p53 act downstream of Nos. We have
previously demonstrated a critical role for oxidative stress in
mediating cell death in our Drosophila model of Alexander
disease8. To explore a possible link between Nos and oxidative
stress in GFAPR79H transgenic ﬂies, we expressed a sensitive
oxidative stress reporter, GstD1-lacZ, in which expression of b-gal
(lacZ) is controlled by the GstD1 promoter and increases in
response to oxidative stress40. When we performed double-label
immunoﬂuorescence for b-gal and cell-type-speciﬁc markers
(repo to identify glia and elav to mark neurons), we detected
activation of the reporter in glia speciﬁcally (Fig. 5a). When we
overexpressed Nos together with GFAPR79H in glia using the
repo-GAL4 driver, we further activated the reporter. Conversely,
knockdown of Nos decreased reporter activation. Overexpressing
Nos in the absence of GFAPR79H did not activate the reporter
(Fig. 5b). These data are consistent with a role for oxidative stress
downstream of Nos in promoting glial toxicity.
NO can promote apoptosis through DNA damage and p53
activation41. To determine whether DNA damage and p53
activation are mediators of cell death in GFAPR79H ﬂies, we
ﬁrst examined levels of the Drosophila DNA damage response
marker phosphorylated H2Av (H2Av-pS137) and p53 using
western blot analyses. Both markers were signiﬁcantly increased
in GFAPR79H transgenic ﬂies compared with aged-matched
control ﬂies (Fig. 6a,c). Immunohistochemical staining also
revealed robust activation of H2Av-pS137 and p53 in
GFAPR79H transgenic ﬂies (Supplementary Fig. 5a,b). Using
double-label immunoﬂuorescence, we determined that both
H2Av-pS137 and p53 were increased in glial cells (Fig. 6b,d).
Further, H2Av-pS137 and p53 colocalized in the same glial cells
(Fig. 6e).
To examine the functional role of p53 in GFAP toxicity, we
reduced p53 levels using either a transgenic RNAi line or a p53
null allele. Both manipulations signiﬁcantly reduced cell death in
GFAPR79H transgenic ﬂies (Fig. 6f). Reducing p53 levels also
signiﬁcantly decreased seizure frequency in GFAPR79H transgenic
ﬂies (Fig. 6g), demonstrating a beneﬁcial effect of modulating
p53 at the organismal level. The reduction of GFAP toxicity was
not due to alterations in GFAP levels, as determined by western
blot analysis (Supplementary Fig. 5d). We conﬁrmed decreased
(p53 RNAi) or absent (p53null) p53 protein expression using
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western blotting and a p53-speciﬁc antibody (Supplementary
Fig. 5e). Reducing p53 levels using transgenic RNAi did not alter
the toxicity of mutant ataxin 3, as monitored by vacuole
formation (Supplementary Fig. 2d), consistent with speciﬁcity
of the rescue of GFAP toxicity. To probe the relationship between
NO signalling and p53, we counted the number of p53-positive
cells in GFAPR79H ﬂies with genetically altered Nos levels.
Overexpression of Nos signiﬁcantly increased the number of
p53-positive cells, while knockdown of Nos decreased the number
of p53-positive cells (Fig. 6h). These ﬁndings together suggest a
role for p53-mediated cell death downstream of Nos activation.
To further test our model, we determined whether increased
levels of p53 can promote death of adult glia in the absence of
transgenic GFAPR79H. Since overexpression of p53 during
development produces organismal lethality, we reduced
developmental expression of p53 using the temperature-sensitive
GAL4 inhibitor GAL80ts (ref. 42). We then observed TUNEL-
positive cell death in ﬂies expressing p53 using the glial
repo-GAL4 driver (Supplementary Fig. 5c). These ﬁndings
conﬁrm the ability of p53 to promote cell death in adult glia,
and taken together with our other results, support a model in
which DNA damage and p53 act downstream of Nos to promote
glial cell death.
We next examined DNA damage and p53 accumulation in
mouse models of Alexander disease. Double-label immunoﬂuor-
escence revealed upregulation of H2AX-pS139, p53 and p53-pS15
in GFAPþ /R236H and GFAPTg mice, but not in age-matched
controls (Fig. 7a–c). H2AX-pS139 colocalized with p53 and
p53-pS15 in mouse models (Fig. 7d). We also observed
colocalization of H2AX-pS139, p53 and p53-pS15 with CNGA4
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(Fig. 7e). These data demonstrate activation of the DNA damage
response in mouse models of Alexander disease, and are
consistent with a role for the pathway downstream of iNOS.
Increased iNOS level and activated p53 in patient tissue.
Having observed upregulation of the iNOS pathway and activation
of p53 in Drosophila, as well as in mouse models of Alexander
disease, we investigated these two pathways in brains from patients
with Alexander disease. Western blot analysis of frontal grey
matter revealed a statistically signiﬁcant increase in iNOS expres-
sion in Alexander disease patients (Fig. 8a). To evaluate the spe-
ciﬁcity of our ﬁndings, we measured iNOS expression by western
blot in frontal grey matter from patients with metachromatic
leukodystrophy patients, a childhood neurological disorder with
some clinical and pathological features in common with Alexander
disease. In contradistinction to our ﬁndings in Alexander disease,
we observed a decrease in iNOS protein levels in metachromatic
leukodystrophy patients (Supplementary Fig. 4h). Consistent with
our ﬁndings in experimental animal models of Alexander disease,
immunohistochemical analysis and double-label immuno-
ﬂuorescence showed a robust and consistent increase in p53 in
astrocytes of brain tissue from all Alexander disease patients
examined (Fig. 8b).
Discussion
Although morphological alterations are characteristic of astro-
cytes (so-called reactive gliosis) in any brain condition with major
parenchymal injury, deﬁning the speciﬁc role astrocytes play in
promoting neuronal pathology has been difﬁcult. Signiﬁcant
neuronal pathology is present in many serious neurological
disorders, including neurodegenerative disease, stroke, epilepsy
and other brain syndromes. Thus, distinguishing between a
primary causal or secondary reactive role for glia in these
pathologies has been difﬁcult. To deﬁne a primary role of
astrocytes in neurodegeneration, we focused here on Alexander
disease. Alexander disease is caused by dominant mutations in
GFAP, an intermediate ﬁlament protein of astrocytes. Therefore,
in Alexander disease neurodegeneration is linked directly to
astrocyte dysfunction5.
Identifying the signalling molecule(s) and pathways that
mediate toxic effects of astrocytes on neurons has been a
second major challenge in understanding the role astrocytes
play in neuronal dysfunction and death43. Here we have used
a ﬂy model of Alexander disease, which replicates major features
of the human disorder8, to perform a forward genetic
screen aimed at identiﬁcation of secreted signalling molecules
that promote neuronal death. Our screen recovered Nos, the
single ﬂy Nos16. We provided strong evidence that NO signalling
through cGMP is activated in our ﬂy model, and using
both genetics and pharmacology we demonstrated that NO
signalling is critical for neuronal death. Importantly, we also
showed activation of the same NO signalling pathway in
astrocytes of well-characterized mouse models of Alexander
disease, as well as upregulation of iNOS in post-mortem
brain samples from patients with Alexander disease. Previous
experiments have demonstrated that STAT3 can bind to the
iNOS promoter and stimulate transcription44. Using a well-
characterized STAT reporter20, we observed upregulation of
STAT in GFAP transgenic ﬂies, suggesting that activation of the
JAK/STAT pathway could contribute to upregulation of Nos in
Alexander disease.
Deﬁning the cell-type-speciﬁc effects of soluble signalling
molecules in vivo has represented a further barrier in under-
standing the molecular mechanisms of glial-based neurodegen-
eration. To address cell-type speciﬁcity, we have developed a
system to independently manipulate gene expression in glia and
in neurons in our Alexander disease Drosophila model (Fig. 3a).
Using the dual-expression system, we provided strong evidence
that glial-derived NO activates cGMP signalling in neurons to
promote neuronal cell death by reducing the NO receptor, sGC,
speciﬁcally in neurons. Interestingly, however, we also found that
knockdown of sGC in neurons reduces glial cell death as well as
neuronal cell death (Fig. 3b). These ﬁndings are consistent with
signalling, perhaps via NO, from neurons back to glia in our
system. A similar ampliﬁcation process based on release of
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neuronal NO has been reported in a cell culture model related to
experimental autoimmune encephalomyelitis45.
Our ﬁndings raise the possibility that non-cell autonomous
nervous system injury in other ‘gliopathic’ disorders might also be
driven by glial-derived NO. Indeed, NO has been implicated in a
variety of neurological diseases with prominent astrocytic
pathology, including Alzheimer’s disease and Parkinson’s
disease46. Genetic deletion of iNOS is neuroprotective in
experimental models of these disorders47,48, supporting a
functional role for the NO pathway in mediating neuronal
pathology. In the current work, we have documented activation of
the DNA damage response downstream of NO production in ﬂy
and mouse models of Alexander disease. Glia in both Drosophila
and mouse models showed nuclear accumulation of p53 and
evidence of DNA damage, as assayed by development of pH2AX/
v-positive foci (Figs 6 and 7). We also found increased levels of
p53 in brains from patients with Alexander disease, supporting
the relevance of our ﬁndings in experimental models to
the human disease. Interestingly, astrocytes from patients
with Alzheimer’s disease also show nuclear accumulation of p53
(ref. 49) and pH2AX50, raising the possibility of similar pathways
of glial pathogenesis in the most common human
neurodegenerative disorder.
In summary, here we have used Drosophila genetics, supported
by analysis of murine models, to implicate NO as a critical
astrocyte-derived neuronal cell death signalling molecule.
We have further provided evidence that NO promotes glial
dysfunction and death through oxidative stress, DNA damage
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and p53 activation, well-documented target pathways in astro-
cytes and other cell types41,51. Importantly, we used
pharmacological inhibition of NO production to support NO
signalling as a potential therapeutic target in Alexander disease,
and possibly in other gliopathies as well. Indeed, abnormal
astrocytes in our Alexander disease models share similarities with
astrocytes in Alzheimer’s disease and pharmacological inhibition
of iNOS with L-NIL provides beneﬁt in a mouse model of
Alzheimer’s disease52,53.
Methods
Drosophila stocks and genetics. All ﬂy crosses were performed at 25 C; adults
were aged at 29 C to increase transgene expression. The following stocks were
obtained from the Bloomington Drosophila Stock Center: repo-GAL4 (glial driver
in the GAL4/UAS system), ET31-QF (glial driver in the Q system), elav-GAL4
(neuronal driver in the GAL4/UAS system), da-GAL4, tubP-GAL80ts, UAS-NosR-
NAi #1 (TRiP.JF03220), UAS-lacZ, UAS-Gyca99B RNAi #1 (TRiP.JF03176),
UAS-Gyca99B RNAi #2 (TRiP.GL01038), UAS-Gycb100B RNAi #2 (TRiP.JF03214),
p5311-1B-1 (p53null) and p53 RNAi (TRiP.JF02153). UAS-Gycb100B RNAi #1
(VDRC #100706) was from the Vienna Drosophila RNAi Center. Additional stocks
used include NosD15 from P. O’Farrell, hid-lacZ (hid20-10-lacZ) from A. Bergmann,
th-GFP from J. Jiang, GstD1-lacZ from D. Bohmann, alrm-GAL4 and mz0709-
GAL4 from M. Freeman, 10XStat92E-GFP from N. Perrimon and UAS-ATXN3-
Q78 from N. Bonini.
UAS-NosRNAi #2 was generated following the second-generation protocol from
the TRiP at the Harvard Medical School by cloning short hairpin targeting Nos into
the VALIUM20 vector. Genetic Services performed embryo injections. Oligo
sequences were as follows: 50-TCGCAGCATTTCACATCGATA-30 (sense
sequence), 50-TATCGATGTGAAATGCTGCGA-30 (antisense sequence). QUAS-
GFAPR79H was constructed by digesting both UAS-GFAPR79H construct8 and the
pQUAST vector34 with EcoRI and NotI, followed by subcloning of the GFAPR79H
fragment into the pQUAST vector. BestGene performed embryo injections.
Transgenic mice. Five-month-old male GFAPTg (Tg73.7) mice6 were used for
western blot and 3-month-old GFAPþ /R236H mice7 and GFAPTg (Tg73.7)6 mice,
both male and female mice in the FVB/N background, were used for
immunoﬂuorescence staining. Same-sex age-matched wild-type littermates were
used as controls. All procedures were approved by the Institutional Animal Care
and Use Committee of the Graduate School of the University of Wisconsin-
Madison. Tauopathy transgenic mice rTg(tauP301L)4510 (ref. 39) were 7 months
old; controls were age-matched littermates not carrying the human tau transgene.
Drug feedings. L-NAME (Cayman chemical) and D-NAME (Sigma) were
dissolved in water at 5 and 10mM (Fig. 2c,d) and then mixed with instant
Drosophila medium (Carolina Biological). Newly eclosed ﬂies were fed on drug-
embedded food for a total of 15 days for TUNEL analysis and 3 days for seizure
quantiﬁcation. Flies were transferred to new drug-embedded food every 3 days.
Behavioural analysis. Flies were collected under CO2 anaesthesia at 1 day after
eclosion and kept at ﬁve animals per vial for 1 day, without further anaesthesia,
before analysis. Drug-fed ﬂies were kept on drug-embedded food for 3 days before
analysis. For testing, vials were mechanically stimulated on a VWR mini vortexer
for 10 s at maximum speed. Seizures were deﬁned as repetitive contractions of legs
or wings, or episodes of paralysis lasting more than 1 s (refs 8,54). Seizure
frequency was calculated by dividing the number of ﬂies with seizures by the total
number of ﬂies tested. Statistical signiﬁcance was evaluated using the w2-test. Each
data point represents seizure frequency (% of ﬂies with seizures).
Immunostaining and TUNEL analysis. For tissue sections, adult ﬂies were ﬁxed in
formalin and embedded in parafﬁn. Four-micrometre serial frontal sections were
prepared through the entire ﬂy brain and placed on a single glass slide. In some
studies, whole-mount Drosophila brain preparations were alternatively used.
Mouse brains were ﬁxed in 4% paraformaldehyde, embedded in parafﬁn and
sectioned at a thickness of 6 mm.
For immunostaining, parafﬁn slides were processed through xylene, ethanol
and into water. Antigen retrieval by boiling in sodium citrate, pH 6.0, was
performed before blocking. Slides were blocked in PBS containing 0.3% Triton
X-100 and 2% milk for 1 h and then incubated with appropriate primary antibodies
overnight. Antibodies are summarized in Supplementary Table 1. For
immunohistochemistry, biotin-conjugated secondary antibodies (1:200,
SouthernBiotech) and the avidin-biotin-peroxidase complex (Vectastain Elite,
Vector Laboratories) staining was performed using DAB (Vector Laboratories) as a
chromagen. For double-labelling studies, secondary antibodies coupled to Alexa
488 or Alexa 555 (1:200, Invitrogen) were used. All immunostaining data were
replicated in at least three animals, and representative images are shown.
As a control, diluted polyclonal nitrotyrosine antibody22–24 was incubated with
nitrated BSA (Upstate; ﬁnal concentration 1mgml 1) for 2 h at room temperature
before being applied to tissue; the control was incubated with non-nitrated BSA
(ﬁnal concentration 1mgml 1). To reduce nitrotyrosine to aminotyrosine, tissue
was incubated with 10mM or 50mM dithiothreitol diluted in PBS for 10min at
100 C; the control was incubated with PBS36. A dose-dependent reduction in
immunoreactivity was observed (Supplementary Fig. 4b).
Apoptotic cell death was visualized using TUNEL labelling according to the
manufacturer’s instructions (TdT FragEL DNA fragmentation kit, Calbiochem),
with an additional avidin-biotin-peroxidase ampliﬁcation step. The number of
TUNEL-positive cells was counted by examining serial frontal sections (4 mm) of
the entire brains from at least six animals per genotype or condition. Fluorescent
TUNEL labelling was performed with Alexa 488-conjugated streptavidin
(Invitrogen). Data are presented as both cell counts (Figs 2a,c and 3b) and fold
changes (Supplementary Figs 2a,i and 3g) to facilitate assessment of the magnitude
of the changes observed. Statistical analysis was performed using one-way analysis
of variance (ANOVA) with Tukey’s multiple comparison test. Each data point
represents the mean±s.e.m. The nuclear morphology of TUNEL-positive cells
(Supplementary Fig. 2d) was evaluated with 4,6-diamidino-2-phenylindole (DAPI)
staining in six GFAP transgenic ﬂies.
Quantiﬁcation of the number of b-gal-positive cells for hid-lacZ activation, the
number of GFP-positive cells for th-GFP activation and the number of cleaved
Dcp-1-positive cells (Supplementary Fig. 2e–g) was performed by examining serial
frontal sections (4mm) of the entire brains from at least six animals per genotype.
Quantiﬁcation of the number of b-gal-positive cells for GstD1-lacZ activation
(Fig. 5b) and the number of p53-positive cells (Fig. 6h) was performed by counting
the positive cells in one complete optic lobe from at least six animals per genotype.
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple
comparison test. Each data point represents the mean±s.e.m.
NADPH-diaphorase staining. The NADPH-diaphorase staining protocol was
adapted from Ott and Elphick55. Brieﬂy, brains were dissected in PBS and ﬁxed in
freshly mixed methanol and formalin (1:1) for 2 h on ice, followed by rinsing in
PBS. Brains were then incubated in a PBS solution containing 0.3% Triton X-100,
0.5mM NADPH (Sigma) and 0.2mM NBT (Fisher). Incubations were carried out
ﬁrst in a cold room and then at room temperature until a proper blue developed.
Brains were rinsed with PBS and images were acquired using a SPOT camera. Six
brains for each genotype were analysed. Each data point represents the
mean±s.e.m.
NO measurement. The NO chemical sensor FL2E (Strem Chemicals) was
dissolved in dimethylsulphoxide (DMSO) and mixed with CuCl2 immediately
before use to form Cu2(FL2E)19. Brains were dissected in PBS and added to 10 mM
Cu2(FL2E). Time-lapse imaging was performed for each brain on a SPOT camera
with an interval of 2min for a total of 10min. Seven brains for each genotype were
dissected and imaged. ImageJ was used to quantify ﬂuorescence intensity, and
two-way ANOVA with the Bonferroni post test was used for statistical analysis.
Each data point represents the mean±s.e.m.
cGMP measurement. A single ﬂy head was homogenized in sample buffer and
then centrifuged at 600g for 15min at 4 C. The supernatant was used for
determination of cGMP concentration following the manufacturer’s instructions
(aCella-cGMP immunoassay, Cell Technology). Each data point represents the
mean±s.e.m.
Western blots. For standard western blot analysis, adult Drosophila heads were
homogenized in 1 Laemmli buffer (Sigma). For murine samples, cortex was
homogenized in homogenization buffer (50mM Tris, 150mM NaCl, pH 7.4, with
protease inhibitor cocktail, Thermo Scientiﬁc) and centrifuged at 100,000g for 1 h
at 4 C. The supernatant was used for western blot. For human brains, grey matter
from the frontal cortex was homogenized in homogenization buffer and cen-
trifuged at 100,000g for 1 h at 4 C. The supernatant was used for western blots. For
nitrated BSA (Upstate), serial dilutions were made in PBS and then added to
Laemmli buffer (Sigma) at the indicated concentrations (Supplementary Fig. 4b).
Samples were boiled for 10min at 100 C, brieﬂy centrifuged and subjected to
SDS–polyacrylamide gel electrophoresis using 10% or 4–12% gels (Lonza). Proteins
were transferred to nitrocellulose membranes (Bio-Rad), blocked in 2% milk in
PBS with 0.05% Tween-20 and immunoblotted with primary antibodies
(Supplementary Table 1). The appropriate anti-mouse or anti-rabbit horseradish
peroxidase-conjugated secondary antibody (1:50,000, SouthernBiotech) was
applied and the signal was detected with West Femto chemiluminescent substrate
(Thermo Scientiﬁc). All blots were repeated at least three times, and representative
blots are presented in the ﬁgures. Full-length images of cropped blots are shown in
Supplementary Figs 6 and 7. Western blots were quantiﬁed with NIH Image J
software, and statistical analysis was performed using the unpaired t-test (two
samples) or one-way ANOVA with Tukey’s multiple comparison test (three or
more samples). Each data point represents the mean±s.e.m.
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Human samples. Frozen frontal cortex from ﬁve controls (mean age 10 years,
range 1–28 years; 2 females and 3 males), ﬁve Alexander disease patients (mean age
13 years, range 1–27 years; 2 females and 3 males) and four metachromatic
leukodystrophy patients (mean age 10 years, range 3–21 years; 2 females and 2
males) were obtained from the NICHD Brain and Tissue Bank for Developmental
Disorders at the University of Maryland, Baltimore, MD. Informed consent for
tissue distribution was obtained by the NICHD Brain and Tissue Bank. The studies
were performed under IRB-approved protocol 2003P000813 from Partners
Healthcare to M.B. Feany. GFAP mutations in the Alexander disease patients
included R79C, R239H (2 cases), K63E and L359V. All cases had typical neuro-
pathology of Alexander disease, including multiple Rosenthal ﬁbres. Post-mortem
intervals were comparable between cases and controls and were less than 24 h in all
cases. For immunostaining analysis, tissue was thawed and ﬁxed in 4% paraf-
ormaldehyde overnight before parafﬁn embedding.
Confocal microscopy. All the ﬂuorescent images were taken as Z-stacks on a
confocal microscope (a Zeiss LSM 510 or a Leica SP8 X confocal microscope at
Harvard NeuroDiscovery Center Enhanced Neuroimaging Core facility or an
Olympus Fluoview 1000 confocal microscope at Harvard Medical School Neuro-
biology Imaging facility, NINDS P30 Core Center grant #NS072030) and visualized
in two-dimensional projections of Z-stacks. Control and experimental samples
were imaged with the same laser setting and the same Z-stack thickness.
Real-time PCR. RNA was isolated from Drosophila head homogenates using
QIAzol (Qiagen) and reverse-transcribed using the High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems) according to the manufacturer’s
instruction. Real-time PCR was performed and monitored using SYBR Green PCR
Master Mix (Applied Biosystems) in a StepOnePlus Real-Time PCR system
(Applied Biosystems) according to the manufacturer’s instructions. Drosophila
ribosomal protein RpL32 was used as a control. Each data point represents the
mean±s.e.m.
Primers:
Gyca99B: 50-GTGGCCAAGTACCGCCAGA-30; 50-CGCTGGCCTCGTCCAT
CT-30
Gycb100B: 50-AATCGTTCAGGCCGGCA-30; 50-CGAAGTTGAGCTGCAG
GTGC-30
Rpl32: 50-GACCATCCGCCCAGCATAC-30 ; 50-CGGCGACGCACTCTGTT-30-
Statistical analysis. GraphPad Prism (v5) was used to perform two-tailed
unpaired Student’s t-tests (for two groups), one-way ANOVA with Tukey’s post
hoc tests (for three groups or more) and two-way ANOVA with Bonferroni’s post
test (for two variables). GraphPad QuickCalcs (a web tool) was used to perform a
w2-test (for comparison between observed frequency and expected frequency).
Po0.05 was considered statistically signiﬁcant. No statistical methods were used to
predetermine sample sizes; sample sizes were similar to those reported in prior
publications. Variance within each group was not calculated, but assumed to be
similar. All photomicrographs shown (immunolabelling, light microscopy and
blots) are representative of at least three biological replicates. All quantitative data
are presented as mean±s.e.m., except for seizure frequency (percentage of ﬂies
with seizures). Data for all experiments were collected and processed randomly, but
no formal randomization was carried out. Data collection and analysis were not
performed blind given the nature of the experiments performed.
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